Comparative Pharmacology
Head-to-head clinical analysis: OXCARBAZEPINE EXTENDED RELEASE TABLETS versus TEGRETOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXCARBAZEPINE EXTENDED RELEASE TABLETS versus TEGRETOL.
OXCARBAZEPINE EXTENDED RELEASE TABLETS vs TEGRETOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by blocking voltage-sensitive sodium channels, inhibiting repetitive firing of action potentials, and reducing the propagation of synaptic impulses. Also modulates calcium channels and enhances potassium conductance.
Voltage-gated sodium channel blocker; stabilizes neuronal membranes and inhibits repetitive firing. Also inhibits glutamate release and enhances GABA activity.
Initial: 300 mg orally twice daily. Increase by up to 600 mg/day at weekly intervals. Target maintenance: 1200-2400 mg/day in two divided doses. Extended-release tablets are dosed once daily: initial 600 mg, titrate weekly by 600 mg to maintenance 1200-2400 mg once daily.
Initial: 200 mg orally twice daily; increase by 200 mg/day at weekly intervals. Maintenance: 800-1200 mg/day in 2-4 divided doses. Maximum dose: 1600 mg/day. Extended-release: 200-400 mg twice daily.
None Documented
None Documented
Oxcarbazepine: ~2 hours (not clinically relevant due to rapid conversion to MHD). MHD: ~9 hours (steady-state achieved in 2-3 days).
Single dose: 25–65 hours (mean ~35 h); chronic therapy: 12–17 hours due to autoinduction; clinical context: requires 3–4 weeks to reach steady-state after dose adjustment.
Renal: ~70% (mainly as glucuronide conjugates of MHD and oxcarbazepine, with <1% unchanged oxcarbazepine and ~27% unchanged MHD). Fecal: <1%.
Primarily hepatic metabolism; ~72% excreted in urine (as metabolites, <2% unchanged), ~28% excreted in feces via bile.
Category C
Category C
Anticonvulsant
Anticonvulsant